Recent Updates
Recently added Catalysts

Mesalamine

Phase 1

Healthy | Small molecule | Other |Takeda Pharmaceutical Company Limited|Last Updated: Jun 3, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLED
Total Trials1
Total Enrollment18
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02125292Taste Assessment Study of SHP429 in Healthy Adult SubjectsPHASE1 COMPLETED 18Jun 2, 2014Jun 19, 2014Jun 3, 20211 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Positive Responses to Palatability Assessment of The Taste of Mesalamine
Immediately post-dose

A taste assessment was completed immediately after investigational product was administered to assess the subject's taste/liking of the formulation. The assessment consisted of a 5-point rating scale. Participants were asked to choose one of the following responses to the statement "The taste was acceptable": strongly agree, agree, neutral, disagree, or strongly disagree. The number of participants who chose either of the top two responses (strongly agree, agree) is reported.

Number of Participants Who Detected an Aftertaste of Mesalamine
5 minutes post-dose

An aftertaste assessment was completed 5 minutes after administration of investigational product to assess whether the participants detected an aftertaste. The participants answered "Yes" or "No" to the following question: "Was there an aftertaste?" The number of participants who answered "Yes" is reported.

Number of Participants With Positive Responses to Palatability Assessment of The Aftertaste of Mesalamine
5 minutes post-dose

An aftertaste assessment was completed 5 minutes after administration of investigational product to assess the subject's rating of aftertaste and means of administration. The assessment consisted of a 5-point rating scale. The participants were asked to choose one of the following responses to the statement "The aftertaste (if present) was acceptable": strongly agree, agree, neutral, disagree, or strongly disagree. The number of participants who chose either of the top two responses (strongly agree, agree) is reported.

Number of Participants Willing to Take Mesalamine Via Treatment Method on a Regular Basis
Immediately post-dose

The participants were asked to answer "Yes" or "No" to the following question: "Would you be willing to take medicine this way on a regular basis if necessary?" The number of participants who answered "Yes" is reported.

Secondary Endpoints
Number of Participants Who Experienced an Adverse Event
4 days
Number of Participants With Potentially Clinically Important Laboratory Results
1 day
Number of Participants With Potentially Clinically Important Vital Signs
1 day
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER
Treatment Arms
ArmTypeDescription
Mesalamine (Vanilla Yogurt)EXPERIMENTALOne 500mg capsule contents sprinkled onto 1 tablespoon of low-fat vanilla yogurt
Mesalamine (Applesauce)EXPERIMENTALOne 500mg capsule contents sprinkled onto 1 tablespoon of applesauce
Mesalamine (Dosing Cup)EXPERIMENTALOne 500mg capsule contents emptied into a dosing cup and taken with water
Interventions
NameTypeDescription
MesalamineDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * normal, healthy, adult male and female volunteers, without evidence of active or chronic disease

Countries:United States
Unlock Eligibility Criteria